wire - news in brief

« BACK

Economics/Business



Results 351 - 400 of 425.


Pharmacology - Economics / Business - 24.04.2013
Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth
Sustained commitment to innovation resulted in eight key approvals in the EU and US and strong pipeline progress EMA approved Jetrea, Bexsero , a new indication for Ilaris and a line extension for Ex

Economics / Business - 14.03.2013

Economics / Business - Health - 22.02.2013
Shareholders approve all resolutions proposed by Novartis Board of Directors - Dr. Joerg Reinhardt to succeed as Chairman following transition period
Shareholders approve 16 th consecutive dividend increase to CHF 2.30 (+2%) per share for 2012, representing a payout of approximately 65% of net income from continuing operations New compensat

Economics / Business - 19.02.2013
Novartis Board of Directors and Dr. Daniel Vasella agree to cancel the non-compete agreement and all related compensation; Decision taken to address concerns of stakeholders
Basel, 19 February 2013 - Novartis announced that the Novartis Board of Directors and Dr. Daniel Vasella have agreed to cancel his non-compete agreement with Novartis and all related conditional compensation.

Innovation - Economics / Business - 24.09.2012
Nexthink, EPFL spin-off
Pedro Bados, co-founder of Nexthink, EPFL spin-off, dreams of making the region a breeding ground for start-ups.

Health - Economics / Business - 19.07.2012
Novartis second quarter results enhance future growth prospects with eight significant regulatory milestones; on track to deliver 2012 outlook
Group net sales increased 1% in constant currencies (cc), with growth in recently launched products more than offsetting loss from Diovan patent expiration Core operating income of USD 3.9 bil

Innovation - Economics / Business - 04.06.2012
CERN adopts new scheme for easy access to intellectual property
CERN adopts new scheme for easy access to intellectual property Geneva, 4 June 2012.

Economics / Business - 30.05.2012

Economics / Business - Pharmacology - 02.05.2012
Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company globally and in the US
Acquisition of Fougera makes Sandoz, the generics division of Novartis, the number one generic dermatology medicines company globally and in the US, strengthening Sandoz's differentiated products str

Economics / Business - 24.04.2012
Nestlé finances a research project
Nestlé finances a research project
Philippe Wieser will conduct a research project that studies the value chain performances Supported by the general management of Nestlé, the project entitled " A convergent approach on sustainable va

Innovation - Economics / Business - 23.04.2012

Economics / Business - Career - 11.04.2012
Roche sends open letter to Illumina shareholders
Roche sends open letter to Illumina shareholders Letter recommends Illumina shareholders vote the GOLD proxy card Roche today sent an open letter to shareholders of Illumina, Inc.

Economics / Business - Pharmacology - 06.04.2012
Roche disappointed with ISS recommendation
Roche disappointed with ISS recommendation Urges Illumina shareholders to vote the GOLD proxy card Roche released the following statement in response to a report issued by Institutional Shareholder Services ("ISS") recommending that shareholders of Illumina, Inc.

Economics / Business - Health - 04.04.2012
Roche sends second letter to Illumina shareholders
Roche sends second letter to Illumina shareholders Letter urges Illumina shareholders to tender shares into Roche's increased offer and vote the GOLD proxy card Roche today sent a second letter to shareholders of Illumina, Inc.

Economics / Business - Career - 03.04.2012
Roche disappointed by Illumina, Inc.’s Board of Directors’ rejection
Roche disappointed by Illumina, Inc.'s Board of Directors' rejection By not engaging with Roche, Illumina reinforces notion of an entrenched Board Roche released the following statement in response to the announcement by Illumina, Inc.

Economics / Business - Health - 26.03.2012
Roche extends tender offer for Illumina
Roche extends tender offer for Illumina Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc.

Economics / Business - Innovation - 20.03.2012
Roche files definitive proxy statement
Roche files definitive proxy statement Letter urges Illumina shareholders to tender shares into Roche's offer and vote the GOLD proxy card Roche today announced that it filed its definitive proxy statement and sent a letter to shareholders of Illumina, Inc.

Economics / Business - Health - 13.03.2012
Roche receives request for additional information from the Federal Trade Commission
Roche receives request for additional information from the Federal Trade Commission Roche announced today that it has received a request for additional information, often referred to as a "second req

Economics / Business - 29.02.2012
Brian McNamara Named Division Head, Novartis OTC
Brian McNamara, who has held several key positions in the Novartis OTC business over the past 7 years, succeeds Naomi Kelman Basel, February 29, 2012 - Novartis named Brian McNamara to the position of Division Head of Novartis OTC (Over-the-Counter), effective immediately.

Innovation - Economics / Business - 10.02.2012
"You have to go global, and right from the start."
How do you go about setting up a business? Hervé Lebret, start-up specialist and head of the Innogrant program at EPFL, answers a few questions.

Economics / Business - Career - 31.01.2012
Roche to nominate slate of independent directors for election at Illumina, Inc.’s 2012 annual meeting
Roche to nominate slate of independent directors for election at Illumina, Inc.'s 2012 annual meeting Election of director nominees and approval of other proposals would result in Roche-nominated dir

Health - Economics / Business - 27.01.2012

Economics / Business - Health - 26.01.2012
Roche responds to adoption of shareholder rights plan by Illumina Board of Directors
Roche responds to adoption of shareholder rights plan by Illumina Board of Directors Roche today responded to an announcement from Illumina, Inc.

Pharmacology - Economics / Business - 13.01.2012
Novartis to restructure US business
Novartis to restructure US business to strengthen competitive position in light of loss of Diovan patent and announces charge for Rasilez /Tekturna.

Innovation - Economics / Business - 11.01.2012
2011: A successful year for spin-offs
Once again, a positive trend in setting up new companies — last year, employees and graduates of ETH Zurich founded 22 spin-offs.

Economics / Business - Innovation - 10.01.2012
Keeping the supply chain moving smoothly
Too much, or… too little! Many companies need to work on improving their supply chains. EPFL researchers have analyzed the best strategies and proven that good supply chain coordination can result in significant savings.

Pharmacology - Economics / Business - 08.01.2012
Novartis recalls certain over-the-counter products in the US
The recall is precautionary following consumer complaints of chipped and broken pills and inconsistent bottle packaging line clearance practices possibly resulting in mixed tablets There have been no

Economics / Business - 28.11.2011
New book on Optimal Control Theory
Thomas Weber published a new book at MIT Press, which gives a rigorous introduction to optimal control theory, with an emphasis on applications in economics. Content This book bridges optimal control theory and economics, discussing ordinary differential equations, optimal control, game theory, and mechanism design in one volume.

Health - Economics / Business - 25.10.2011
Novartis achieves strong third quarter financial performance and pipeline progress
Novartis sales rose 12% and core operating income grew 15% in constant currencies in the third quarter, delivering operating leverage Net sales increased 18% (+12% in constant currencies, or cc) to U

Economics / Business - Event - 04.10.2011

Economics / Business - 03.10.2011
Frontiers of Entrepreneurship Research
Frontiers of Entrepreneurship Research
The co-edited volume "Frontiers of Entrepreneurship Research 2010" (Zacharakis, A. et al.), Babson College, Babson Park, MA, 2010, has been published.

Economics / Business - Pharmacology - 13.09.2011
Novartis increases growth potential through integration of Alcon
Novartis presented an update on its long-term strategy, performance and vision for continued sustainable growth and gave an in-depth overview on the unique position and business model of the new Alcon Division.

Health - Economics / Business - 19.07.2011
Novartis delivers strong financial results and four major approvals in second quarter of 2011
Novartis achieved 19% sales growth in constant currencies and excellent operating leverage in the second quarter Net sales grew 27% (+19% in constant currencies, or cc) to USD 14.9 billion; fi

Pharmacology - Economics / Business - 16.06.2011
Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia
Novartis AG holds groundbreaking ceremony with Minister of Economic Development of the Russian Federation, E. Nabiullina, Governor of Saint - Petersburg V. Matvienko, and Novartis AG CE

Astronomy / Space Science - Economics / Business - 15.06.2011

Economics / Business - 31.05.2011
An effort to curb the IT industry's energy appetite
An effort to curb the IT industry’s energy appetite
Launched today, the ecocloud consortium brings several EPFL laboratories together to tackle the skyrocketing electricity demands of Internet data processing centers.

Pharmacology - Economics / Business - 18.05.2011
Novartis provides restated consolidated income statement data for 2010 and Q1 2011 following the merger with Alcon; no change to total reported Group data
Basel, May 18, 2011 - Novartis provides unaudited restated and pro forma consolidated income statement data after the completion of the merger with Alcon, Inc. The segmental consolidated income statement data has been amended to reflect the new divisional structure following the Alcon merger. The new reporting structure will be effective from the second quarter of 2011.

Economics / Business - 18.05.2011
From one crisis to the next the banks have difficulty in adapting
From one crisis to the next the banks have difficulty in adapting
Can the financial sector regulate itself? A study carried out by EPFL's Swiss Finance Institute, involving 350 American institutions, shows that those that perform poorly in times of crisis will also be adversely affected the next time.

Health - Economics / Business - 19.04.2011
Novartis makes strong start for the year
Novartis generates strong sales growth of 14% in constant currencies in first quarter, operating income impacted by 2010 sales from A(H1N1) pandemic flu vaccines Core operating income up 4% (+6% cc) t

Economics / Business - 08.04.2011
Novartis completes merger with Alcon
Novartis shares required in transaction total 165 million shares instead of 215 shares million following purchase of Alcon shares in open market The 108 million new shares in combination with an addi

Economics / Business - 08.04.2011
Novartis shareholders approve merger of Alcon into Novartis
Shareholder approval clears path for transaction close Shareholders approve the issuance of up to 108 million new shares to be used as part of the transaction Basel, April 8, 2011 - Novartis sharehol

Economics / Business - Pharmacology - 22.03.2011
Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China
Novartis acquires 85 percent stake in Tianyuan, one of the largest privately held vaccines companies in China Novartis to collaborate with Tianyuan on strengthening its existing product portfolio and

Economics / Business - Pharmacology - 17.02.2011
Novartis appoints Naomi Kelman as new Head of the Novartis OTC division
Novartis OTC (Over-the-Counter) to become separate division in the group's diversified healthcare portfolio with Kelman reporting to Joseph Jimenez, CEO of Novartis Basel , February 17, 2011 - Novart